Want to see SE:BACTI.B full AI Analyst Report?
Top Page
Bactiguard Holding AB
(BACTI.B)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr17.00
▼(-11.92% Downside)
Action:Reiterated
Date:07/15/26
The score is primarily held back by weak financial performance quality despite improvement—loss-making results (negative net income and EBIT) and compressed gross margin outweigh the positives of solid EBITDA and a return to positive TTM free cash flow. Technicals are moderately supportive with price above key moving averages and neutral-to-positive momentum, while valuation remains unattractive due to a negative P/E and no stated dividend yield.
Positive Factors
Defensible IP & licensing model
Bactiguard's BIP noble-metal coating and licensing model let it monetize IP without owning mass manufacturing. That structure supports scalable royalty streams, broad partner adoption, and lower capital intensity, preserving cash and enabling steady revenue expansion as partners roll out coated devices.
Negative Factors
Ongoing net losses and negative EBIT
Persisting negative net income and EBIT show the company has not yet translated operational improvements into bottom-line profitability. This limits retained-earnings growth, may require external funding for strategic initiatives, and raises execution risk until core operations consistently generate positive net income.
Read all positive and negative factors
Positive Factors
Negative Factors
Defensible IP & licensing model
Bactiguard's BIP noble-metal coating and licensing model let it monetize IP without owning mass manufacturing. That structure supports scalable royalty streams, broad partner adoption, and lower capital intensity, preserving cash and enabling steady revenue expansion as partners roll out coated devices.
Read all positive factors
Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr543.18M
Dividend YieldN/A
Average Volume (3M)77.61K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth-13.72%
EPS Growth52.47%
CountrySE
Employees168
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume120,571
30 Day Avg. Volume77,614
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)kr212.37M
Bactiguard Holding AB Business Overview & Revenue Model
Company Description
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HA...
How the Company Makes Money
Bactiguard makes money primarily through two revenue streams tied to its infection-prevention technology and product sales. (1) Technology licensing: Bactiguard licenses its BIP coating technology to medical device manufacturers, who incorporate t...
Bactiguard Holding AB Financial Statement Overview
Summary
Income Statement
43
Neutral
Balance Sheet
58
Neutral
Cash Flow
51
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 205.08M | 215.92M | 243.68M | 203.99M | 223.56M | 169.49M |
| Gross Profit | 32.95M | 184.65M | 207.71M | 139.98M | 180.14M | 130.80M |
| EBITDA | 38.61M | 45.15M | 24.99M | -89.98M | -543.00K | -5.94M |
| Net Income | -8.76M | -7.84M | -29.82M | -138.38M | -52.88M | -58.77M |
Balance Sheet | ||||||
| Total Assets | 522.85M | 545.06M | 655.91M | 662.17M | 807.70M | 849.29M |
| Cash, Cash Equivalents and Short-Term Investments | 43.52M | 44.26M | 116.73M | 123.22M | 197.73M | 217.59M |
| Total Debt | 157.09M | 162.92M | 227.77M | 233.10M | 238.70M | 247.96M |
| Total Liabilities | 218.40M | 230.13M | 327.57M | 309.00M | 311.99M | 307.84M |
| Stockholders Equity | 304.45M | 314.93M | 328.34M | 353.18M | 495.71M | 541.45M |
Cash Flow | ||||||
| Free Cash Flow | 8.56M | -7.21M | 10.21M | -60.94M | -7.86M | -38.00K |
| Operating Cash Flow | 13.90M | -1.49M | 24.99M | -52.33M | 3.06M | 7.26M |
| Investing Cash Flow | -5.34M | -5.72M | -14.78M | -8.61M | -10.92M | -7.29M |
| Financing Cash Flow | -13.02M | -62.74M | -21.20M | -11.84M | -13.89M | 205.83M |
Bactiguard Holding AB Technical Analysis
Negative
19.30
Price Trends
16.32
Negative
16.52
Negative
16.91
Negative
Market Momentum
-0.03
Positive
43.45
Neutral
31.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Negative. The current price of 19.3 is above the 20-day moving average (MA) of 16.16, above the 50-day MA of 16.32, and above the 200-day MA of 16.91, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 31.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BACTI.B.
Bactiguard Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | kr1.27B | 42.74 | 6.93% | ― | -0.27% | 93.40% | |
52 Neutral | kr543.18M | -65.83 | -2.52% | ― | -13.72% | 52.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr600.56M | -4.79 | -36.55% | ― | 27.40% | 26.07% | |
48 Neutral | kr212.28M | -4.27 | -18.55% | ― | 0.31% | -26.18% | |
46 Neutral | kr858.27M | -22.59 | -4.42% | ― | -0.34% | 29.54% |
* Healthcare Sector Average
SE:BACTI.B
Bactiguard Holding AB
15.80
-12.30
-43.77%
SE:SEZI
Senzime AB
3.88
-2.37
-37.92%
SE:CRAD.B
C-Rad AB Class B
37.50
3.10
9.03%
SE:INTEG.B
Integrum AB Class B
8.28
-32.40
-79.65%
SE:SEDANA
Sedana Medical AB
8.75
-5.85
-40.07%
Bactiguard Holding AB Corporate Events
Bactiguard deepens BD partnership as Q2 sales and wound care growth strengthen outlook
Jul 14, 2026
Bactiguard reported solid second-quarter 2026 momentum, with total revenue up 9% to SEK 57.1 million and net sales rising 16% adjusted for currency, driven by a strong rebound in BD-related business and record performance in its Wound Management p...
Bactiguard Issues and Repurchases Class C Shares to Fund 2026 Incentive Plan
Jul 8, 2026
Bactiguard Holding AB’s board has moved to secure share delivery under its long-term incentive plan for 2026 by issuing and immediately repurchasing 715,000 Class C shares. The transaction follows authorisations granted at the May annual gen...
Bactiguard to Present Q2 2026 Interim Report in Investor Audiocast
Jul 7, 2026
Bactiguard Holding AB will publish its interim report for the second quarter of 2026 on 14 July at 07:00 CET, followed by an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind and CFO Patrick Bach will present the result...
Bactiguard AGM Backs Board, New Incentive Program and Share Buyback Mandate
May 19, 2026
Bactiguard’s Annual General Meeting approved the 2025 income statement and balance sheet, decided to retain earnings with no dividend, and granted discharge from liability to the Board and CEOs. Shareholders also confirmed the current Board ...
Bactiguard and BD Deepen Global Foley Catheter Partnership to Expand Infection-Prevention Reach
May 11, 2026
Bactiguard Holding AB has restated and modernized its long-running global licensing agreement with medical technology giant BD for Bactiguard-coated Foley catheters designed to reduce catheter-associated infections. The updated long-term deal, whi...
Bactiguard Absorbs Q1 Revenue Hit as Partnerships and Regulatory Push Underpin Growth Plan
Apr 23, 2026
Bactiguard reported first-quarter 2026 revenue of SEK 46.9 million, down 25% year on year, with net sales falling 28% and an operating loss widening to SEK 7.2 million, pressured by significant negative currency effects. Despite lower volumes, the...
Bactiguard Calls 2026 AGM, Proposes No Dividend and New Incentive Program
Apr 17, 2026
Bactiguard Holding AB has called its Annual General Meeting for 19 May 2026 in Stockholm, outlining participation rules for shareholders, including record date registration, notice requirements, and procedures for proxy representation and trustee-...
Bactiguard Sets 2030 Growth Targets as It Shifts to License-Based MedTech Model
Apr 16, 2026
Bactiguard is a global MedTech company specializing in infection prevention, primarily through an ultra-thin noble metal coating that prevents bacterial attachment and biofilm formation on medical devices. Its technology, validated over more than ...
Bactiguard Sets Audiocast for First-Quarter 2026 Results
Apr 15, 2026
Bactiguard Holding AB, the Stockholm-headquartered infection-prevention MedTech company, will publish its interim report for the first quarter of 2026 on 23 April at 07:00 CET. The group’s technology, based on an ultra-thin noble metal coati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.